Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Osteoporos Int. 2017 Jan 16;28(3):767–774. doi: 10.1007/s00198-017-3906-6

Table 2.

Relationship between adherence* and response to daily treatment with oral risedronate (25)

Tablets taken Mean % change Responders, %
<26 -36 56
26-52 -42 59
52-78 -49 72
78-104 -62 64
>104 -63 87
*

Adherence measured at 48 weeks. Responders are considered the individual patients that show changes in BTMs that exceed the LSC.